Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.
Revenue (Most Recent Fiscal Year) | $0.65M |
Net Income (Most Recent Fiscal Year) | $-49.50M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 83.46 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.08 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -7569.42% |
Net Margin (Trailing 12 Months) | -7569.42% |
Return on Equity (Trailing 12 Months) | -253.48% |
Return on Assets (Trailing 12 Months) | -62.88% |
Current Ratio (Most Recent Fiscal Quarter) | 1.53 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.53 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.53 |
Inventory Turnover (Trailing 12 Months) | 1.72 |
Book Value per Share (Most Recent Fiscal Quarter) | $0.10 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.06 |
Earnings per Share (Most Recent Fiscal Year) | $-0.33 |
Diluted Earnings per Share (Trailing 12 Months) | $-0.52 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 128.43M |
Free Float | 94.27M |
Market Capitalization | $54.58M |
Average Volume (Last 20 Days) | 0.65M |
Beta (Past 60 Months) | 0.49 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 26.60% |
Percentage Held By Institutions (Latest 13F Reports) | 23.28% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |